Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 1.00 |
| ▸ | F2R | P25116 | 5/20 | 0.68 |
| ▸ | DHFR | P00374 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30252213 | 1.00 | SLC2A1 (1.00) | SLC2A1F2RDHFR | |
| SCHEMBL28678386 | 0.83 | SLC2A1 (0.73) | SLC2A1F2RDHFR | |
| SCHEMBL24166418 | 0.81 | F2R (1.00) | SLC2A1F2RDHFR | |
| SCHEMBL11614190 | 0.80 | SLC2A1 (0.77) | SLC2A1F2RDHFR | |
| SCHEMBL24166728 | 0.80 | SLC2A1 (0.67) | SLC2A1F2RDHFR | |
| SCHEMBL24165755 | 0.79 | SLC2A1 (0.65) | SLC2A1F2RDHFR | |
| SCHEMBL11614277 | 0.78 | SLC2A1 (1.00) | SLC2A1F2RDHFR | |
| SCHEMBL16210655 | 0.78 | F2R (0.81) | SLC2A1F2RDHFR | |
| SCHEMBL28676490 | 0.78 | SLC2A1 (0.64) | SLC2A1F2RDHFR | |
| SCHEMBL25074391 | 0.78 | SLC2A1 (0.64) | SLC2A1F2RDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963959-B2 | Inhibitors for coronavirus | SOUTHWEST RESEARCH INSTITUTE (US) | 2024-04-23 | — | — | US | claimed |
| US-20230295164-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295164-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230242540-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-08-03 | — | — | US | disclosed |
| US-20230242540-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-08-03 | — | — | US | disclosed |
| US-20230065024-A1 | INHIBITORS FOR CORONAVIRUS | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023023469-A1 | INHIBITORS FOR CORONAVIRUS | SOUTHWEST RESEARCH INSTITUTE (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022006432-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2022006447-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2022-01-06 | — | — | WO | disclosed |
| EP-1633754-B1 | DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7226915-B2 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229890-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PTPRO, PTPN18 | SLC2A1 293/4885F2R 4251/4885DHFR 531/4885 |
| US-20230295164-A1 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | CFTR, MRPL21, MPO | SLC2A1 3013/4885F2R 3396/4885DHFR 538/4885 |
| US-11963959-B2 | Inhibitors for coronavirus | ACE, ACE2, SARS1 | SLC2A1 3281/4885F2R 360/4885DHFR 456/4885 |
| US-20230242540-A1 | COMPOUNDS HAVING ANTICANCER ACTIVITY | TP53, KRAS, MKI67 | SLC2A1 4036/4885F2R 4267/4885DHFR 183/4885 |
| US-20230065024-A1 | INHIBITORS FOR CORONAVIRUS | ACE, ACE2, SARS1 | SLC2A1 3281/4885F2R 360/4885DHFR 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.